LB Pharmaceuticals (LBRX) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases.

• Lead product candidate, LB-102, is a methylated derivative of amisulpride, designed to improve efficacy and tolerability with strong intellectual property protection.

• LB-102 is Phase 3-ready for acute schizophrenia and is being developed for additional indications including bipolar depression and potentially major depressive disorder.

• Pipeline includes plans for a long-acting injectable (LAI) formulation to address compliance issues in psychiatric populations.

• Strategy includes U.S. and international development, with plans to retain commercialization rights in the U.S. and potentially partner ex-U.S.

Financial performance and metrics

• No revenue generated to date; company is pre-commercial and has incurred recurring losses since inception.

• Net losses: $63.1 million (2024), $6.3 million (2023), $10.2 million (six months ended June 30, 2025).

• Accumulated deficit as of June 30, 2025: $114.5 million.

• Cash and cash equivalents as of June 30, 2025: $14.2 million; pro forma as adjusted after IPO: $242.7 million.

• Research and development expenses: $51.2 million (2024), $7.8 million (2023); general and administrative expenses: $13.7 million (2024), $3.5 million (2023).

Use of proceeds and capital allocation

• Estimated net proceeds from IPO: $228.5 million (or $263.4 million if underwriters' option exercised in full), based on $15.00 per share.

• Approximately $133 million allocated to advance LB-102 through Phase 3 trial in acute schizophrenia and NDA-enabling studies.

• Approximately $25 million allocated to Phase 2 trial in bipolar depression.

• Remainder for general corporate purposes, with potential for in-licensing or acquisitions.

• Proceeds, together with existing cash, expected to fund operations through Q1 2028.